Smoking cessation and cardiovascular disease risk factors: Results from the third national health and nutrition examination survey

PLoS Medicine

Volumn 2, Issue 6, 2005, Pages 0528-0536

  Bakhru, Arvind ^a,b   Erlinger, Thomas P ^c,d,e  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; ESTROGEN; FIBRINOGEN; NONSTEROID ANTIINFLAMMATORY AGENT; SERUM ALBUMIN;

ADULT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MALE; NUTRITION; REVIEW; SMOKING CESSATION; ARTICLE; BLOOD; CROSS-SECTIONAL STUDY; METABOLISM; MIDDLE AGED; RISK FACTOR; RISK REDUCTION; SMOKING; UNITED STATES;

ADULT; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NUTRITION SURVEYS; RISK FACTORS; RISK REDUCTION BEHAVIOR; SERUM ALBUMIN; SMOKING; SMOKING CESSATION; UNITED STATES;

EID: 22144442811     PISSN: 15491277     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020160     Document Type: Review

References (61)

1. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105: 1135-1143.
2. Szmitko PEB, Wang CHM, Weisel RDM, Jeffries GAB, Anderson TJM, et al. (2003) Biomarkers of vascular disease linking inflammation to endothelial activation. Circulation 108: 2041-2048.
3. Bottcher M, Falk E (1999) Pathology of the coronary arteries in smokers and non-smokers. J Cardiovasc Risk 6: 299-302.
4. Howard G, Burke GL, Szklo M, Tell GS, Eckfeldt J, et al. (1994) Active and passive smoking are associated with increased carotid wall thickness. The Atherosclerosis Risk in Communities Study. Arch Intern Med 154: 1277-1282.
5. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, et al. (2002) Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: Prospective analysis from the Women's Health Initiative observational study. JAMA 288: 980-987.
6. Kuller LH, Tracy RP, Shaten J, Meilahn EN (1996) Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 144: 537-547.
7. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332: 635-641.
8. de Maat MP, Pietersma A, Kofflard M, Sluiter W, Kluft C (1996) Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 121: 185-191.
9. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, et al. (1999) CReactive protein, a sensitive marker of in.ammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99: 237-242.
10. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349: 462-466.
11. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ (1993) Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 342: 1076-1079.
12. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, et al. (2000) Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ 321: 199-204.
13. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of Creactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565.
14. Strandberg TE, Tilvis RS (2000) C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol 20: 1057-1060.
15. Ridker PM, Koenig W, Fuster V (2004) C-reactive protein and coronary heart disease. N Engl J Med 351: 295-298.
16. Blake GJ, Ridker PM (2002) C-reactive protein, subclinical atherosclerosis, and risk of cardiovascular events. Arterioscler Thromb Vasc Biol 22: 1512-1513.
17. Yasojima K, Schwab C, Mcgeer EG, Mcgeer PL (2001) Generation of Creactive protein and complement components in atherosclerotic plaques. Am J Pathol 158: 1039-1051.
18. Zwaka TP, Hombach V, Torzewski J (2001) C-reactive protein-mediated low density lipoprotein uptake by macrophages-Implications for atherosclerosis. Circulation 103: 1194-1197.
19. Nakajima T, Schulte S, Warrington KJ, Kopecky SL, Frye RL, et al. (2002) Tcell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 105: 570-575.
20. Ratnam S, Mookerjea S (1998) The regulation of superoxide generation and nitric oxide synthesis by C-reactive protein. Immunology 94: 560-568.
21. Kilpatrick JM, Volanakis JE (1991) Molecular genetics, structure, and function of C-reactive protein. Immunol Res 10: 43-53.
22. Kushner I, Jiang SL, Zhang D, Lozanski G, Samols D (1995) Do posttranscriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1? Ann N Y Acad Sci 762: 102-107.
23. Agrawal A, Cha-Molstad H, Samols D, Kushner I (2003) Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. Immunology 108: 539-547.
24. Cha-Molstad H, Agrawal A, Zhang D, Samols D, Kushner I (2000) The Rel family member P50 mediates cytokine-induced C-reactive protein expression by a novel mechanism. J Immunol 165: 4592-4597.
25. Weinhold B, Bader A, Poli V, Ruther U (1997) Interleukin-6 is necessary, but not sufficient, for induction of the humanC-reactive protein gene in vivo. Biochem J 325: 617-621.
26. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, et al. (2002) A selfful fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106: 913-919.
27. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, et al. (2004) Creactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between Creactive protein and cardiovascular disease. Circulation 109: 2058-2067.
28. Pasceri V, Cheng JS, Willerson JT, Yeh ET (2001) Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103: 2531-2534.
29. Chakraborti T, Mandal A, Mandal M, Das S, Chakraborti S (2000) Complement activation in heart diseases. Role of oxidants. Cell Signal 12: 607-617.
30. Blaschke F, Bruemmer D, Yin F, Takata Y, Wang W, et al. (2004) C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 110: 579-587.
31. Fu T, Borensztajn J (2002) Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: Possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem J 366: 195-201.
32. Rigotti NA, Pasternak RC (1996) Cigarette smoking and coronary heart disease: Risks and management. Cardiol Clin 14: 51-68.
33. National Center for Health Statistics (1994) Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Washington (DC): U.S. Government Printing Office. Available: http:// www.cdc.gov/nchs/data/ series/sr_01/sr01_032.pdf. Accessed 27 April 2005.
34. National Center for Health Statistics (1996) Analytic and reporting guidelines: The Third National Health and Nutrition Examination Survey, NHANES III (1988-94). Hyattsville (Maryland): National Center for Health Statistics. Available: http://www.cdc.gov/nchs/data/nhanes/nhanes3/ nh3gui.pdf. Accessed 19 April 2005.
35. Wu T, Buck GM, Mendola P (2003) Blood lead levels and sexual maturation in U.S. girls: the Third National Health and Nutrition Examination Survey, 1988-1994. Environ Health Perspect 111: 737-741.
36. Ford ES, Gillespie C, Ballew C, Sowell A, Mannino DM (2002) Serum carotenoid concentrations in US children and adolescents. Am J Clin Nutr 76: 818-827.
37. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282: 2131-2135.
38. Erlinger TP, Guallar E, Miller ER 3rd, Stolzenberg-Solomon R, Appel LJ (2001) Relationship between systemic markers of inflammation and serum beta-carotene levels. Arch Intern Med 161: 1903-1908.
39. Aberg A, Bergstrand R, Johansson S, Ulvenstam G, Vedin A, et al. (1983) Cessation of smoking after myocardial infarction. Effects on mortality after 10 years. Br Heart J 49: 416-422.
40. Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, Creactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 279: 1477-1482.
41. Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, et al. (1999) Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J 20: 954-959.
42. Cook DG, Shaper AG, Pocock SJ, Kussick SJ (1986) Giving up smoking and the risk of heart attacks. A report from The British Regional Heart Study. Lancet 2: 1376-1380.
43. van Berkel TFM, Boersma H, De Baquer D, Deckers JW, Wood D (1999) Registration and management of smoking behaviour in patients with coronary heart disease-The EUROASPIRE survey. Eur Heart J 20: 1630-1637.
44. Omenn GS, Anderson KW, Kronmal RA, Vlietstra RE (1990) The temporal pattern of reduction of mortality risk after smoking cessation. Am J Prev Med 6: 251-257.
45. Meade TW, Imeson J, Stirling Y (1987) Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 2: 986-988.
46. Dobson AJ, Alexander HM, Heller RF, Lloyd DM (1991) How soon after quitting smoking does risk of heart attack decline? J Clin Epidemiol 44: 1247-1253.
47. Rosenberg L, Palmer JR, Shapiro S (1990) Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 322: 213-217.
48. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, et al. (1997) Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 17: 2167-2176.
49. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK (2003) Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 138: 891-897.
50. Pearson TA (2002) New tools for coronary risk assessment: What are their advantages and limitations? Circulation 105: 886-892.
51. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, et al. (2004) Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351: 2599-2610.
52. Ablij HC, Meinders AE (2003) Atherosclerosis and inflammation: The role of C-reactive protein. Ned Tijdschr Geneeskd 147: 15-20.
53. Benowitz NL (2003) Cigarette smoking and cardiovascular disease: Pathophysiology and implications for treatment. Prog Cardiovasc Dis 46: 91-111.
54. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, Masoura C, et al. (2004) Effect of exposure to secondhand smoke on markers of inflammation: The ATTICA study. Am J Med 116: 145-150.
55. Pechacek TF, Babb S (2004) How acute and reversible are the cardiovascular risks of secondhand smoke? BMJ 328: 980-983.
56. Law MR, Morris JK, Wald NJ (1997) Environmental tobacco smoke exposure and ischaemic heart disease: An evaluation of the evidence. BMJ 315: 973-980.
57. Eliasson B, Hjalmarson A, Kruse E, Landfeldt B, Westin A (2001) Effect of smoking reduction and cessation on cardiovascular risk factors. Nicotine Tob Res 3: 249-255.
58. Vallance P, Collier J, Bhagat K (1997) Infection, inflammation, and infarction: Does acute endothelial dysfunction provide a link? Lancet 349: 1391-1392.
59. World Health Organization (2005) Why is tobacco a public health priority? Available: http://www.who.int/tobacco/health_priority/en/. Accessed 19 April 2005.
60. Lightwood JM, Glantz SA (1997) Short-term economic and health benefits of smoking cessation: Myocardial infarction and stroke. Circulation 96: 1089-1096.
61. World Health Organization (2005) Global tobacco treaty enters into force with 57 countries already committed. Available: http://www.who.int/ mediacentre/news/releases/2005/pr09/en/index.html. Accessed 19 April 2005.